目的 探讨人干扰素a2b阴道泡腾片联合匹多莫德口服液治疗宫颈持续性高危型人乳头瘤病毒(human papilloma virus,HPV)感染的临床效果。方法 选取2019-01至2020-12经解放军总医院第三医学中心妇产科确诊为宫颈持续性高危型HPV感染患者211例,依据治疗方案分为两组,联合治疗组109例,给予人干扰素a2b阴道泡腾片联合匹多莫德口服液治疗,对照组102例,给予人干扰素a2b阴道泡腾片单药治疗,观察两组治疗后6、12个月宫颈高危HPV转归情况。结果 治疗后6个月联合治疗组HPV有效率(全部转阴率)为51.38%(56/109),明显高于对照组HPV有效率23.53%(24/102),差异有统计学意义(P<0.05);治疗后12个月联合治疗组HPV有效率为73.39%(80/109),对照组HPV有效率为42.16%(43/102),差异有统计学意义(P<0.05)。进一步分析两组未转阴HPV分型,治疗后12个月,联合治疗组HPV16/18、HPV52和HPV58转阴例数均多于对照组。结论 人干扰素a2b阴道泡腾片联合匹多莫德口服液可提高宫颈高危型HPV转阴率,且对于清除宫颈HPV16/18型感染更有效。
Abstract
Objective To investigate the clinical efficacy of human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid in the treatment of persistent cervical high-risk type human papilloma virus (HPV).Methods A total of 211 cases with persistent cervical high-risk type HPV infection diagnosed in the Third Medical Center of PLA General Hospital were collected from January 2019 to December 2020, and they were randomly divided into two groups according to treatment options. The experimental group of 109 cases were treated with human interferon a2b vaginal effervescent tablets combined with pidotimod oral liquid, while the control group of 102 cases were treated with human interferon a2b vaginal effervescent tablets as single-agent therapy. The outcomes of cervical high-risk HPV at 6 months and 12 months after treatment were compared between the two groups.Results The effective rate (all negative conversion rate) of HPV was 51.38% (56/109) in the experimental group and 23.53% (24/102) in the control group after 6 months’ treatment, and there was a significant difference between the two groups (P<0.05).The effective rate of HPV was 73.39% (80/109) in the experimental group and 42.16% (43/102) in the control group after 12 months’ treatment, and there was a significant difference between the two groups (P<0.05). Further analysis of HPV typing remaining positive in the experimental group and the control group was conducted, and the effective rate of the top three types (HPV16/18, HPV52 and HPV58) after treatment in the experimental group was better than that in the control group.Conclusion Human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid can effectively improve the negative conversion rate of cervical high-risk type HPV, and more effective for removal of cervical HPV16/18 infection, which provides a reference for clinical treatment of HPV persistent infection.
关键词
宫颈高危型人乳头瘤病毒 /
HPV转归 /
免疫治疗 /
人干扰素 /
匹多莫德
Key words
cervical high-risk human papilloma virus /
outcome of HPV /
immunotherapy /
human interferon /
pidotimod
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Lortet T J,Georges D,Bray F,et al.Profiling global cancer incidence and mortality by socioeconomic development[J].Int J Cancer,2020,147(11):3029-3036.
[2] 郭思洁,田黎黎,孔 琪,等.武昌区域单中心人乳头瘤病毒感染及不同基因型的分布特征[J].中国实用妇科与产科杂志,2019,35(1):123-126.
[3] Harper D M,Franco E L,Wheeler C,et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a fandomised controlled trial[J].Lancet,2004,364(9447):1757-1765.
[4] 张一萍,星丽娜,张云鹤.治疗性人类乳头瘤病毒疫苗研究进展[J].武警医学,2021,32(10):901-906.
[5] 于筱卿,赵 瑾,王国庆.干扰素联合重组人干扰素α-2b凝胶对HPV持续阳性的效果观察[J].中国生化药物杂志,2016,36(1):98-100.
[6] 陈 光,张 黎.消疣汤结合干扰素α-2b凝胶治疗高危型人乳头瘤病毒感染宫颈病变疗效观察[J].现代中西医结合杂志,2019,28(23):2563-2565.
[7] Hou S,Yuan L,Jin P,et al.A clinical study of the effects of lead poisoning on the intelligence and neurobehavioral abilities of children[J]. Theor Biol Med Model,2013,10:13.
[8] 李春琳,张红平,王应海,等.hTERT基因多态性与宫颈癌前病变关联性研究[J].中华肿瘤防治杂志,2019,26(18):1323-1328.
[9] 王登海,陈忠萍,居 峰,等.TCT联合HPV-DNA及端粒酶检测在宫颈癌前病变评估中的应用价值[J].检验医学与临床,2017,14(21):3193-3194.
[10] WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention[OL].[2021-07-07]https://www.who.int/publications/i/ite m/9789240030824.
[11] 吴月利,陆仲女,王聪平.妇科门诊患者宫颈癌筛查认知程度及其影响因素[J].武警医学,2020,31(6):479-482.
[12] 周雅轩.免疫促进剂匹多莫德的临床应用进展[J].天津药学,2018,30( 5):58-61.
[13] Zhang L,Bi Q, Deng H,et al. Human papilloma virus infection among women with cervical lesions and cervical cancer in eastern China:genotype-specific prevalence and attribution[J]. BMC Infect Dis, 2017,17(1):107.
[14] 宋 磊,付晓宇.多型别人乳头瘤病毒感染与宫颈癌[J].中国计划生育和妇产科,2016,8(10):12-14.
[15] 宋建东,宋静慧,于聪祥,等.影响宫颈病变患者HPV转归的多因素分析[J].中国实用妇科与产科杂志,2018,34(8):892-897.
[16] 王秀芳,赵 辉.人乳头瘤病毒感染和阴道微生态状况对宫颈鳞状上皮内病变的影响[J].中华医院感染学杂志,2021,31(2):268-271.
PDF(1257 KB)
